Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Product › Details

Cytovir™ CMV

Products Next higher product group T cell therapy_o
Period Status 2013-07-26 development p2 existent
Organisation Organisation Cell Medica Ltd.
  Group Cell Medica (Group)
     

Cell Medica Ltd.. (7/26/13). "Press Release: Cell Medica Announces Completion of Patient Recruitment in the Randomized Cytomegalovirus, CMV~ACE/ASPECT study". London.

Completion of patient recruitment in Phase II clinical study investigating Cytovir™CMV


Cell Medica today announced the completion of recruitment in the CMV~ACE/ASPECT study, a randomized stage Phase II clinical study investigating Cytovir™ CMV.

The CMV~ACE/ASPECT study is a phase II randomized study to investigate the use of adoptive cellular therapy (ACT) in combination with conventional antiviral therapy for the treatment of CMV reactivation episodes in patients following allogeneic hematopoietic stem cell transplant from an unrelated donor. The study recruited over 33 months in 9 centers across the UK. Results will be available January 2014 after the 6 months follow-up period of the patients. The principal investigator of the study is Dr. Karl Peggs, Reader in Stem Cell Transplantation and Immunotherapy at UCL Cancer Institute and Honorary Consultant in Haematology & Transplantation at UCLH NHS Hospitals Foundation Trust.

The CMV~ACE/ASPECT study represents a collaboration between Leukaemia & Lymphoma Research, a UK charity dedicated to research into blood cancers including leukemia, lymphoma and myeloma, University of Birmingham, and UCL (University College London).

Dr. Karl Peggs commented: “This is a major achievement within the field of adoptive cellular immunotherapy, and one which the international community has been watching with interest. Delivering recruitment of a complex cellular therapy study on time and in budget is no minor accomplishment, and one that owes much to the concerted collaborative efforts of all partners involved. I would like to extend my personal thanks to our funders, our collaborators in Birmingham, to the international bone marrow donor registries, and to the team at Cell Medica. Equally importantly, I would like to thank the patients, their donors, and the transplant teams around the UK for their continued support of this study, without which we would not have been able to get this far. Our hope is that we will establish a new standard of care for patients undergoing allogeneic stem cell transplantation. I am sure that I am not the only one awaiting the final results early next year with keen anticipation.”


Notes to Editors:


About Cell Medica

Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, Cytovir™CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following allogeneic bone marrow transplant, is available in the UK and is under development in other territories. Cytovir™ ADV is being developed for the treatment of adenovirus infections in pediatric patients following bone marrow transplantation. Cell Medica is also working with the Center for Cell and Gene Therapy, Baylor College of Medicine, to develop Cytorex™ EBV for the treatment of malignancies associated with the oncogenic Epstein Barr Virus.


About T cell immunotherapy

T cell immunotherapy involves harnessing the power and precision of the human immune system to treat disease. Extensive academic research in the field of clinical immunology has provided early evidence that T cells may be used for the treatment of viral infections. Certain cancers are also associated with infection by viruses such as the Epstein Barr Virus (EBV). Ongoing clinical research at UCL, Baylor College of Medicine and other institutions is exploring how T cell immunotherapy may be used to eliminate malignant cells which express viral antigens.


About Cytovir CMV

Cytovir CMV is available on clinician’s request (UK only). It is comprised of naturally occurring CMV-specific cytotoxic T lymphocyte cells (T cells) that are directly selected from a seropositive donor. Cytovir CMV is under development by Cell Medica as a novel treatment for cytomegalovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplantation by means of virus-specific immune reconstitution.


About UCL (University College London)

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender and the first to provide systematic teaching of law, architecture and medicine.

We are among the world’s top universities, as reflected by our performance in a range of international rankings and tables. According to the Thomson Scientific Citation Index, UCL is the second most highly cited European university and the 15th most highly cited in the world.

UCL has nearly 27,000 students from 150 countries and more than 9,000 employees, of whom one third are from outside the UK. The university is based in Bloomsbury in the heart of London, but also has two international campuses – UCL Australia and UCL Qatar. Our annual income is more than £800 million.


For more information, please contact:

Gregg Sando, CEO, Cell Medica Limited
info@cellmedica.co.uk
+44 (0)20 7554 4070

Date
26th July 2013

   
Record changed: 2015-08-14

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for T cell therapy_o


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top